| Primary information |
|---|
| sequence ID | Seq_1203 |
| Peptide sequence | DEAGSEADHEGTHSTKRGH |
| CancerPDF_ID | CancerPDF_ID8539, CancerPDF_ID9691, CancerPDF_ID10427, |
| PMID | 23667664,21533267,21805675 |
| Protein Name | Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Serum,Urine |
| M/Z | 2019.86,674.28,2020.8813 |
| Charge | 1,3,NA |
| Mass (in Da) | 2022.01,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF |
| Peptide Identification technique | FT-ICR MS/MS + nano-HPLC,LC/MS/MS,MALDI-TOF-MS |
| Quantification Technique | NA,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,1.49,1 |
| CancerPDF_ID | CancerPDF_ID8539, CancerPDF_ID9691, CancerPDF_ID10427, |
| p-Value | NA,NA,NA |
| Software | MASCOT,MASCOT,NA |
| Length | 19,19,19 |
| Cancer Type | "Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Muscle-invasive bladder cancer |
| Database | NA,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA |
| Number of Patients | "Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,751 bladder cancer and 127 control |
| Regulation | NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal",Differentially expressed between cancer vs normal samples |
| Validation | NA,MRM-based validation of 19 candidates,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |